Core Insights - Merck & Co., Inc. is recognized as a strong immunotherapy investment by hedge funds, with Deutsche Bank upgrading its rating to Buy and increasing the price target to $150 from $115, citing undervaluation due to Keytruda's patent concerns [1] Group 1: Company Developments - On February 11, Merck announced FDA approval for KEYTRUDA® and KEYTRUDA QLEX™ in combination with paclitaxel, for treating adults with PD-L1+ platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma [2] - KEYTRUDA QLEX's effectiveness is supported by well-controlled studies and additional data comparing its pharmacokinetic, efficacy, and safety profiles with KEYTRUDA [3] Group 2: Company Overview - Merck is a biopharmaceutical company focused on health solutions for disease treatment and prevention in both humans and animals, with its Pharmaceutical segment offering vaccines and therapeutic products [4]

Core Insights - Merck & Co., Inc. is identified as one of the most undervalued stocks in the Dow, recognized for its leadership in pharmaceuticals, vaccines, biologics, and animal health products [1] Group 1: Recent Developments - The FDA approved KEYTRUDA QLEX, a new subcutaneous injectable formulation of Keytruda, on September 19, 2025, which enhances patient convenience by reducing administration time from 30 minutes to 1-2 minutes [2] - In Europe, Merck received a positive opinion from the European Medicines Agency for ENFLONSIA (clesrovimab), a preventive for RSV in infants, which would be the first weight-independent option for this demographic if approved [3] Group 2: Financial Performance - Merck reported strong Q2 2025 results, with analysts highlighting its robust vaccine franchise, animal health segment, and innovative oncology treatments, including combination therapies with Keytruda [4] - The company is advancing novel drug candidates, such as raludotatug deruxtecan, which has received FDA Breakthrough Therapy Designation for treating platinum-resistant ovarian and related cancers [4]